Soleno Therapeutics (NASDAQ:SLNO) Upgraded by Lifesci Capital to Strong-Buy Rating

Lifesci Capital upgraded shares of Soleno Therapeutics (NASDAQ:SLNO - Free Report) to a strong-buy rating in a research report report published on Tuesday morning,Zacks.com reports. Lifesci Capital also issued estimates for Soleno Therapeutics' Q4 2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($1.67) EPS, Q2 2025 earnings at ($1.13) EPS, Q3 2025 earnings at ($1.03) EPS, Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($3.32) EPS, Q1 2026 earnings at ($1.55) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($1.54) EPS, FY2027 earnings at $5.58 EPS, FY2028 earnings at $9.47 EPS and FY2029 earnings at $9.99 EPS.

SLNO has been the topic of a number of other research reports. Stifel Nicolaus reiterated a "buy" rating and issued a $74.00 price target on shares of Soleno Therapeutics in a research report on Monday, December 2nd. HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Soleno Therapeutics in a research report on Monday, December 2nd. Robert W. Baird restated an "outperform" rating and set a $72.00 target price on shares of Soleno Therapeutics in a research report on Monday, December 2nd. Finally, Oppenheimer upped their target price on Soleno Therapeutics from $65.00 to $73.00 and gave the company an "outperform" rating in a research report on Monday, October 28th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Soleno Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $71.20.

Soleno Therapeutics Stock Down 1.2 %

Shares of NASDAQ SLNO traded down $0.61 during trading on Tuesday, reaching $50.37. The company had a trading volume of 337,128 shares, compared to its average volume of 425,934. The company's fifty day moving average price is $47.18 and its 200-day moving average price is $49.86. Soleno Therapeutics has a 12 month low of $36.61 and a 12 month high of $60.92. The stock has a market cap of $2.17 billion, a P/E ratio of -15.17 and a beta of -1.46.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.83) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by ($1.22). As a group, equities analysts predict that Soleno Therapeutics will post -3.72 earnings per share for the current year.

Insider Activity at Soleno Therapeutics

In other news, CFO James H. Mackaness sold 4,083 shares of Soleno Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $45.41, for a total value of $185,409.03. Following the completion of the transaction, the chief financial officer now directly owns 115,089 shares in the company, valued at approximately $5,226,191.49. The trade was a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bhatnagar Anish sold 10,937 shares of the business's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $45.41, for a total value of $496,649.17. Following the transaction, the chief executive officer now owns 708,616 shares of the company's stock, valued at approximately $32,178,252.56. The trade was a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,360 shares of company stock valued at $790,119. 12.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Soleno Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. AlphaQuest LLC boosted its holdings in shares of Soleno Therapeutics by 1,154.4% in the 4th quarter. AlphaQuest LLC now owns 715 shares of the company's stock worth $32,000 after purchasing an additional 658 shares in the last quarter. US Bancorp DE purchased a new position in shares of Soleno Therapeutics in the 4th quarter worth about $34,000. Avanza Fonder AB purchased a new position in shares of Soleno Therapeutics in the 4th quarter worth about $76,000. Avior Wealth Management LLC bought a new stake in shares of Soleno Therapeutics in the 4th quarter valued at about $89,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Soleno Therapeutics in the 3rd quarter valued at about $155,000. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.